CoChat

Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma

Open access
Grossmann, Kenneth F., Othus, Megan, Patel, Sapna P., Tarhini, Ahmad A., Sondak, Vernon K., Knopp, Michael V., Petrella, Teresa M., Truong, Thach-Giao, Khushalani, Nikhil I., Cohen, Justine V., Buchbinder, Elizabeth I., Kendra, Kari, Funchain, Pauline, Lewis, Karl D., Conry, Robert M., Chmielowski, Bartosz, Kudchadkar, Ragini R., Johnson, Douglas B., Li, Hongli, Moon, James, Eroglu, Zeynep, Gastman, Brian, Kovacsovics-Bankowski, Magdalena, Gunturu, Krishna S., Ebbinghaus, Scot W., Ahsan, Sama, Ibrahim, Nageatte, Sharon, Elad, Korde, Larissa A., Kirkwood, John M., Ribas, Antoni · 2022 · Cancer Discovery
Cited by 111

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

We conducted a randomized phase III trial to evaluate whether adjuvant pembrolizumab for one year (647 patients) improved recurrence-free survival (RFS) or overall survival (OS) in comparison with high-dose IFNα-2b for one year or ipilimumab for up to three years (654 patients), the approved standard-of-care adjuvant immunotherapies at the time of enrollment for patients with high-risk resected melanoma. At a median follow-up of 47.5 months, pembrolizumab was associated with significantly longer RFS than prior standard-of-care adjuvant immunotherapies [HR, 0.77; 99.62% confidence interval (CI), 0.59–0.99; P = 0.002]. There was no statistically significant association with OS among all patients (HR, 0.82; 96.3% CI, 0.61–1.09; P = 0.15). Proportions of treatment-related adverse events of grades 3 to 5 were 19.5% with pembrolizumab, 71.2% with IFNα-2b, and 49.2% with ipilimumab. Therefore, adjuvant pembrolizumab significantly improved RFS but not OS compared with the prior standard-of-care immunotherapies for patients with high-risk resected melanoma. Significance: Adjuvant PD-1 blockade therapy decreases the rates of recurrence, but not survival, in patients with surgically resectable melanoma, substituting the prior standard-of-care immunotherapies for this cancer. See related commentary by Smithy and Shoushtari, p. 599. This article is highlighted in the In This Issue feature, p. 587

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-21-1141

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 111

Metadata

Authors
Grossmann, K. F., Othus, M., Patel, S. P., Tarhini, A. A., Sondak, V. K., Knopp, M. V., Petrella, T. M., Truong, T.-G., Khushalani, N. I., Cohen, J. V., Buchbinder, E. I., Kendra, K., Funchain, P., Lewis, K. D., Conry, R. M., Chmielowski, B., Kudchadkar, R. R., Johnson, D. B., Li, H., Moon, J., Eroglu, Z., Gastman, B., Kovacsovics-Bankowski, M., Gunturu, K. S., Ebbinghaus, S. W., Ahsan, S., Ibrahim, N., Sharon, E., Korde, L. A., Kirkwood, J. M., & Ribas, A.
Venue
Cancer Discovery
Published
2022-03-01
Volume
12
Issue
3
Pages
644-653
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W3214653934
Cited by
111
References
10
FWCI
5.05
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma. https://app.cochat.ai/papers/10.1158/2159-8290.cd-21-1141
The paper
Grossmann, K. F., Othus, M., Patel, S. P., Tarhini, A. A., Sondak, V. K., Knopp, M. V., Petrella, T. M., Truong, T.-G., Khushalani, N. I., Cohen, J. V., Buchbinder, E. I., Kendra, K., Funchain, P., Lewis, K. D., Conry, R. M., Chmielowski, B., Kudchadkar, R. R., Johnson, D. B., Li, H., . . . Ribas, A. (2022). Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-21-1141

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.